Drug Trial Radar · NCT01256658
A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)
Last checked: Nov 19, 2026Latest source record: Feb 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14,075
Actual
Start
Nov 2010
Primary completion
Jul 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on a number of clinical malaria cases in children less than 5 years of age and the improvement of hemoglobin levels in the overall population.
Conditions
- Malaria
Interventions
COA566Drug
COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)Time frame: Month 12 of period 1
- Change in Hemoglobin Level (g/dL) in Asymptomatic Carriers >6 Months of Age (Per Cluster)Time frame: Day 1 and day 28 of period 1
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Burkina Faso, Burkina Faso
Centre National de Recherche et de Formation sur le Paludisme
Ouagadougou, Ouagadougou, Burkina Faso
Novartis Investigative site
Ouagadougou, Ouagadougou, Burkina Faso
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.